Biotech Values

[DewDiligence]

Re: Complexities of the coagulation cascade

By sheer coincidence, Craig Wheeler was talking about this on today’s MNTA webcast.

FXa intervention (Lovenox and other LMH heparins) works great for preventing DVT, but it is ineffective on arterial thrombosis, is not reversible, and is rarely used in the cath lab.

FIIa intervention (Angiomax) works great for preventing arterial thrombosis, but it is ineffective against DVT and impractical for chronic use.

Ordinary (unfractionated) heparin inhibits both FXa and FIIa and is reversible, but it has problems with monitoring and reliability.

MNTA has designed a heparin variant called M118 from the ground up that works on both FXa and FIIa, is reversible, and doesn’t have the monitoring and reliability problems of ordinary heparin. If it works as advertised it will be a monumental blockbuster, but it’s still very early in development.